NCT07424508Enrolling by invitation
Movement State-dependent Adaptive DBS for PD
Movement State-Dependent Adaptive Deep Brain Stimulation for Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to detect the onset of walking by recording neural activities from the motor cortical areas and the globus pallidus, 2) understand the impacts of changes in DBS parameters on gait kinematics and optimize setting parameters for enhancing walking performance, 3) develop a movement state-dependent adaptive deep brain stimulation (DBS) paradigm to automatically switch stimulation settings according to different movement states (i.e., walking vs non-walking). The proposed therapy will deliver personalized neurostimulation based on individual physiological biomarkers to enhance gait function in patients with PD. 6 patients with idiopathic Parkinson's disease who have already been implanted with the Medtronic Summit RC+S device will be enrolled in this study.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 4 Feb 2026
- Primary completion date
- 1 Apr 2030
- Lead sponsor
- Doris Wang, MD, PhD
- Diseases
- Parkinson disease
- NCT number
- NCT07424508
What you commit to
- Study type: Interventional
- Planned participants: 6
- From 4 Feb 2026 to the primary completion date, 1 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to comply with study procedures
- Patients who cannot walk (wheelchair bound)
Who the study is looking for
- Ability to give informed consent for the study
- Subjects implanted with Summit RC+S investigational DBS system.
- Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA)
- Signed informed consent
- Age 21-75
- Diagnosis of idiopathic PD with duration of motor symptoms for 3 years or greater
- Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist.
- UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia. OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management
- Patients with gait impairments: slowed gait, shuffling steps, postural instability, or freezing of gait off medication.
Age in the registry: 21 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCSF Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.